Cobra Develops Scaled-up Process for Novolytics' MRSA Candidate

- Last updated on GMT

Cobra Develops Process for Novolytics MRSA Candidate
Cobra Develops Process for Novolytics MRSA Candidate
UK CMO Cobra Biologics has helped Novolytics prepare for trials of a new phage-based MRSA treatment with a new scaled-up production process.

The new process – specifics of which are being kept confidential – is used to produce clinical supplies of Novolytics lead candidate Novo12, which is a gel-based ‘phage cocktail’ intended to treat superbug infections such as methicillin-resistant Staphylococcus aureus​ (MRSA).

Novolytics transfer existing processes to Cobra’s phage team who managed to increase 100-fold increases in upstream process yields in a project that leveraged the contract manufacturing organisation’s (CMO) existing knowhow, according to CEO Peter Coleman.

“The phage team has considerable experience in developing processes for such novel products and looks forward to working closely with Novolytics.”

Related news

Show more

Related products

Related suppliers

Follow us

Products

View more

Webinars